logo
Sign in

CHROMATAN INC

Dedham, MA · Biotech · Private

Kascade BioRMB, a column-free chromatography platform for biopharmaceutical protein purification

Claim this profile

Follows are private to you and power your alerts

Updated · chromatan.com

Sector
Biotech
Headquarters
Dedham, MA
Latest Form D
$2.7M, Jun 2019
Total capital
$14.2M
Federal grants
$9.2M
11 awards · 2015–2025
Rank in peer group#11 of 13
Private capital raised
$2.7M
1 Form D · last Jun 2019
89 months since last filing
Federal contracts
$2.3M
1 award · Health and Human S
Rank in Biotech#129 of 4373
Granted patents
3
1 pending · first 2019
Rank in peer group#6 of 13

Capital timeline

201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $14.2M$941K$2.3M$1.3M$2.5M$707K$1.3M1st Form D$2.7M
201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $14.2M$2.3M$1.3M$2.5M$1.3M1st Form D$2.7M

Latest events

  • Federal grantHealth and Human S · Phase II · Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$695K
  • Federal grantHealth and Human S · Phase II · Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$214K
  • Federal grantHealth and Human S · Phase II · Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)$1.3M
  • Federal grantHealth and Human S · Phase II · Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$504K
  • Federal grantHealth and Human S · Phase II · Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$707K
  • Federal grantHealth and Human S · Phase II · Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$2.5M
  • Federal grantHealth and Human S · Phase II · Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)$1.3M
  • Private capital raisedForm D · SEC · 1st filing$2.7M
Show 5 earlier federal awards
  • Federal grantHealth and Human S · Phase II · Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$256K
  • Federal grantHealth and Human S · Phase II · Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$540K
  • Federal contractHealth and Human S · Igf::cl::igf Baa Contract$2.3M
  • Federal grantHealth and Human S · Phase II · Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$941K
  • Federal grantHealth and Human S · Phase II · Commercialization of Integrated Continuous and Single-use Bio-production Capture Platform (ICS)$222K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

41months

from CHROMATAN INC’s first federal award to its first private round.

First federal award · Dec 2015
Health and Human S · $222K
First Form D · Jun 2019
$2.7M · 1st Form D
Awards before first raise
5 awards

An association in public records, not a cause or a prediction.

Standing among 13 peers

Line = median

Biotech · System

  • Federal grantsBelow median
  • Granted patents#6 · top 46%
  • Linked publications#5 · top 38%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Oleg ShinkazhResearcherExecutive Officer, DirectorLinked by 3 patents · $9.2M in grants as PI
  • Andrew ZyndeyDirectorNamed in SEC Form D filings
  • Paul SilvisDirectorNamed in SEC Form D filings
  • Steven CarpenterDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 4
Show all 4 patent records

Recent research by its founders

  • Continuous precipitation‐filtration process for initial capture of a monoclonal antibody product using a four‐stage countercurrent hollow fiber membrane washing step202329 cites
  • Improved protein A resin for antibody capture in a continuous countercurrent tangential chromatography system201918 cites
  • Development of integrated continuous bioprocessing using Continuous Countercurrent Tangential Chromatography (CCTC) platform for capture and polishing of monoclonal antibodies20190 cites

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .